{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-094806","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.187697+00:00","generated_at":"2026-05-18T08:52:12.810315+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ultragenyx's UX143 Phase 3 Orbit passes DMC safety review; final analysis year-end 2025","bullets":["DMC confirms acceptable safety profile for UX143 in pediatric/young adult OI patients; study continues to final analysis.","Final analysis of Phase 3 Orbit trial expected around end of 2025, with statistical threshold p<0.04.","Safety in younger patients consistent with prior studies; no data from Cosmic study analyzed at interim.","Patients continue dosing; final analyses after at least 18 months therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-094806","json":"https://secwatch.observer/filing/0000950170-25-094806.json","markdown":"https://secwatch.observer/filing/0000950170-25-094806.md","text":"https://secwatch.observer/filing/0000950170-25-094806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025094806/0000950170-25-094806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025094806/rare-20250709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:52:12.810315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}